Volume 15 - Issue 6 - June 2007

In 1997 the Food and Drug Administration gave indication to the Thin-layer Rapid Use Epicutaneous (T.R.U.E.) test for use as a valuable, first-line screening tool in the diagnosis of allergic contact dermatitis (ACD). Many dermatologists and allergists use this standard tool in their practices and refer to contact dermatitis referral centers when the T.R.U.E test fails to identify a relevant allergen. Specifically, the T.R.U.E. test screens for 46 distinct allergens in addition to the balsam of Peru mixture, and it is thought to adequately identify an allergen in approximately 24.5%